CPH Group (CPHN) Fair Value & Analysis
Basic Materials · CH · Market cap CHF 348M
Fair value as of: Jun 24, 2026
Analysis
CPH Group (CPHN) currently trades at CHF 55.00, while our model-based Fair Value estimate is CHF 49.64 — implying the stock looks roughly 9.7% overvalued today. We read business quality at 95/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
CPH Group AG, together with its subsidiaries, develops, manufactures, and distributes chemical products and packaging solutions for pharmaceutical customers in Europe, Asia, and North and South America. It operates through two segments: Zeochem and Perlen Packaging. The Zeochem segment produces molecular sieves for industrial and medical applications, chromatography gels for the pharmaceutical industry, and deuterated products used in analytics, pharmaceuticals, and OLED displays. This segment also operates production facilities in Switzerland, Bosnia and Herzegovina, the USA, Canada, China, and India. The Perlen Packaging segment focuses on the pharmaceutical industry, supplying coated plastic films used primarily in blister packaging to protect medications, as well as vials and containers for medical use; and PVC mono films and coated PVdC barrier films for use in the pharmaceutical industry. CPH Group AG was founded in 1818 and is based in Perlen, Switzerland.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is CPH Group (CPHN) undervalued?
What is the fair value of CPHN?
What is the quality score of CPHN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.